Matrix metalloproteinases: Contribution to pathogenesis, diagnosis and treatment of periodontal inflammation

Annals of Medicine

Volumn 38, Issue 5, 2006, Pages 306-321

  Sorsa, Timo ^a,g   Tjäderhane, Leo ^a,b   Konttinen, Yrjö T ^a,c,d   Lauhio, Anneli ^a   Salo, Tuula ^b   Lee, Hsi Ming ^e   Golub, Lorne M ^e   Brown, David L ^f   Mäntylä, Päivi ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF OULU   (Finland)

^c ORTON ORTHOPAEDIC HOSPITAL   (Finland)

^d Invalid Foundation ^*  (Finland)

^e STONY BROOK UNIVERSITY   (United States)

^f STONY BROOK UNIVERSITY   (United States)

^g UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Chair side diagnostics; Doxycycline; Gingival crevicular fluid; Inflammation; Matrix metalloproteinase; Periodontal disease

Indexed keywords

COLLAGENASE; COLLAGENASE 3; DOXYCYCLINE HYCLATE; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; NEUTROPHIL COLLAGENASE; STROMELYSIN; STROMELYSIN 2; TISSUE INHIBITOR OF METALLOPROTEINASE;

CLINICAL TRIAL; ENZYME INHIBITION; GENE EXPRESSION; GENETIC POLYMORPHISM; GINGIVITIS; HUMAN; PATHOGENESIS; PERIODONTAL DISEASE; PERIODONTITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN POLYMORPHISM; PROTEIN SECRETION; REVIEW; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TOOTH PLAQUE;

CYTOKINES; DENTAL IMPLANTS; GENE EXPRESSION; HUMANS; MATRIX METALLOPROTEINASES; PERIODONTITIS; PROMOTER REGIONS (GENETICS); PROMOTER REGIONS, GENETIC;

EID: 33748638853     PISSN: 07853890     EISSN: 16512219     Source Type: Journal    
DOI: 10.1080/07853890600800103     Document Type: Review

References (151)

1. Gross J, Lapiere CM. Collagenolytic activity in amphibian tissues: a tissue culture assay. Proc Natl Acad Sci. 1962;48:1014-22.
2. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 2003;92:827-39.
3. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;b:161-74.
4. Murphy G, Knäuper V. Relating matrix metalloproteinase structure to function: why the 'hemopexin' domain? Matrix Biol. 1997;15:511-8.
5. McCawley LJ, Matrisian LM. Matrix metalloproteinases: they're not just for matrix anymore! Curr Opin Cell Biol. 2001;13:534-40.
6. Ala-aho R, Kähäri V-M. Collagenases in cancer. Biochimie. 2005;87:273-86.
7. Golub LM, Wolff M, Roberts S, Lee HM, Leung M, Payonk GS. Treating periodontal diseases by blocking tissue-destructive enzymes. J Am Dent Assoc. 1994;125:163-9; discussion 169-71.
8. Björklund M, Koivunen E. Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta. 2005;25:37-69.
9. Itoh Y, Kajita M, Kinoh H, Mori H, Okada A, Seiki M. Membrane type 4 matrix metallloproteinase (MT4-MMP, MMP-17) is a glycosyl-phosphatidyl inositol-anchored proteinase. J Biol Chem. 1999;274:34260-6.
10. Kojima S, Itoh Y, Matsumoto S, Masuho Y, Seiki M. Membrane-type 6 matrix metalloproteinase is the second glycosyl-phosphatidyl inositol-anchored MMP. FEBS Lett. 2000;480:142-6.
11. Weiss SJ. Tissue destruction by neutrophils. N Eng J Med. 1989;320:365-76.
12. Ding Y, Uitto VJ, Haapasalo M, Lounatmaa K, Konttinen YT, Salo T, et al. Membrane components of Treponema denticola trigger proteinase release from human polymorphonuclear leukocytes. J Dent Res. 1996;75:1986-93.
13. Ding Y, Haapasalo M, Kerosuo E, Lounatmaa K, Kotiranta A, Sorsa T. Release and activation of human neutrophil matrix metallo- and serine proteinases during phagocytosis of Fusobacterium nucleatum, Porphyromonas gingivalis and Treponema denticola. J Clin Periodontol. 1997;24:237-48.
14. Weiss SJ, Peppin G, Ortiz X, Ragsdale C, Test ST. Oxidative autoactivation of latent collagenase by human neutrophils. Science. 1985;227:747-9.
15. Hanemaaijer R, Sorsa T, Konttinen YT, Ding Y, Sutinen M, Visser H, et al. Matrix metalloproteinase-8 is expressed in rheumatoid synovial fibroblasts and endothelial cells. Regulation by tumor necrosis factor-alpha and doxycycline. J Biol Chem. 1997;272:31504-9.
16. Saari H, Suomalainen K, Lindy O, Konttinen YT, Sorsa T. Activation of latent human neutrophil collagenase by reactive oxygen species and serine proteases. Biochem Biophys Res Commun. 1990;171:979-87.
17. Cole AA, Kuettner KE. MMP-8 (neutrophil collagenase) mRNA and aggrecanase cleavage products are present in normal and osteoarthritic human articular cartilage. Acta Orthop Scand, 98-102.
18. Cole AA, Chubinskaya S, Schumacher B, Huch K, Szabo G, Yao J, et al. Chondrocyte matrix metalloproteinase-8. Human articular chondrocytes express neutrophil collagenase. J Biol Chem. 1996;271:11023-6.
19. Chubinskaya S, Huch K, Mikecz K, Cs-Szabo G, Hasty KA, Kuettner KE, et al. Chondrocyte matrix metalloproteinase-8: up-regulation of neutrophil collagenase by interleukin-1 beta in human cartilage from knee and ankle joints. Lab Invest. 1996;74:232-40.
20. Palosaari H, Wahlgren J, Larmas M, Ronka H, Sorsa T, Salo T, et al. The expression of MMP-8 in human odontoblasts and dental pulp cells is down-regulated by TGF-beta1. J Dent Res. 2000;79:77-84.
21. Tervahartiala T, Pirilä E, Ceponis A, Maisi P, Salo T, Tuter G, et al. The in vivo expression of the collagenolytic matrix metalloproteinases (MMP-2, -8, -13, and -14) and matrilysin (MMP-7) in adult and localized juvenile periodontitis. J Dent Res. 2000;79:1969-77.
22. Prikk K, Maisi P, Pirilä E, Reintam MA, Salo T, Sorsa T, et al. Airway obstruction correlates with collagenase-2 (MMP-8) expression and activation in bronchial asthma. Lab Invest. 2002;82:1535-45.
23. Prikk K, Maisi P, Pirila E, Sepper R, Salo T, Wahlgren J, et al. In vivo collagenase-2 (MMP-8) expression by human bronchial epithelial cells and monocytes/macrophages in bronchiectasis. J Pathol. 2001;194:232-8.
24. Wahlgren J, Maisi P, Sorsa T, Sutinen M, Tervahartiala T, Pirila E, et al. Expression and induction of collagenases (MMP-8 and -13) in plasma cells associated with bone-destructive lesions. J Pathol. 2001;194:217-24.
25. Moilanen M, Pirilä E, Grenman R, Sorsa T, Salo T. Expression and regulation of collagenase-2 (MMP-8) in head and neck squamous cell carcinomas. J Pathol. 2002;197:72-81.
26. Bachmeier BE, Nerlich AG, Boukamp P, Lichtinghagen R, Tschesche H, Fritz H, et al. Human keratinocyte cell lines differ in the expression of the collagenolytic matrix metalloproteinases-1,-8, and -13 and of TIMP-1. Biol Chem. 2000;38:509-16.
27. Kiili M, Cox SW, Chen HY, Wahlgren J, Maisi P, Eley BM, et al. Collagenase-2 (MMP-8) and collagenase-3 (MMP-13) in adult periodontitis: molecular forms and levels in gingival crevicular fluid and immunolocalisation in gingival tissue. J Clin Periodontol. 2002;29:224-32.
28. Sorsa T, Tjäderhane L, Salo T. Matrix metalloproteinases (MMPs) in oral diseases. Oral Dis. 2004;10:311-8.
29. Balbin M, Fueyo A, Tester AM, Pendas AM, Pitiot AS, Astudillo A, et al. Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. Nat Genet. 2003;35:252-7.
30. Owen CA, Hu Z, Lopez-Otin C, Shapiro SD. Membrane-bound matrix metalloproteinase-8 on activated polymorphonuclear cells is a potent, tissue inhibitor of metalloproteinase-resistant collagenase and serpinase. J Immunol. 2004;172:7791-803.
31. Gueders MM, Balbin M, Rocks N, Foidart JM, Gosset P, Louis R, et al. Matrix metalloproteinase-8 deficiency promotes granulocytic allergen-induced airway inflammation. J Immunol. 2005;175:2589-97.
32. Freije JM, Diez-Itza I, Balbin M, Sanchez LM, Blasco R, Tolivia J, et al. Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas. J Biol Chem. 1994;269:16766-73.
33. Knäuper V, Lopez-Otin C, Smith B, Knight G, Murphy G. Biochemical characterization of human collagenase-3. J Biol Chem. 1996;271:1544-50.
34. Johansson N, Kähäri VM. Matrix metalloproteinases in squamous cell carcinoma. Histol Histopathol. 2000;15:225-37
35. Kähäri VM, Saarialho-Kere U. Matrix metalloproteinases and their inhibitors in tumour growth and invasion. Ann Med. 1999;31:34-45.
36. Konttinen YT, Salo T, Hanemaaijer R, Valleala H, Sorsa T, Sutinen M, et al. Collagenase-3 (MMP-13) and its activators in rheumatoid arthritis: localization in the pannus-hard tissue junction and inhibition by alendronate. Matrix Biol. 1999;18:401-12.
37. Lindy O, Konttinen YT, Sorsa T, Ding Y, Santavirta S, Ceponis A, et al. Matrix metalloproteinase 13 (collagenase 3) in human rheumatoid synovium. Arthritis Rheum. 1997;40:1391-9.
38. Ylipalosaari M, Thomas GJ, Nystrom M, Salhimi S, Marshall JF, Huotari V, et al. Alpha v beta 6 integrin down-regulates the MMP-13 expression in oral squamous cell carcinoma cells. Exp Cell Res. 2005;309:273-83.
39. Westerlund U, Ingman T, Lukinmaa PL, Salo T, Kjeldsen L, Borregaard N, et al. Human neutrophil gelatinase and associated lipocalin in adult and localized juvenile periodontitis. J Dent Res. 1996;75:1553-63.
40. Ma J, Kitti U, Hanemaaijer R, Teronen OP, Sorsa TA, Natah S, et al. Gelatinase B is associated with peri-implant bone loss. Clin Oral Implants Res. 2003;14:709-13.
41. Makela M, Salo T, Uitto VJ, Larjava H. Matrix metalloproteinases (MMP-2 and MMP-9) of the oral cavity: cellular origin and relationship to periodontal status. J Dent Res. 1994;73:1397-406.
42. Beklen A, Laine M, Venta I, Hyrkäs T, Konttinen YT. Role of TNF-{alpha} and its receptors in pericoronitis. J Dent Res. 2005;84:1178-82.
43. Beklen A, Tuter G, Sorsa T, Hanemaaijer R, Virtanen I, Tervahartiala T, et al. Gingival tissue and crevicular fluid cooperation in adult periodontitis. J Dent Res. 2006;85:59-63.
44. Ingman T, Tervahartiala T, Ding Y, Tschesche H, Haerian A, Kinane DF, et al. Matrix metalloproteinases and their inhibitors in gingival crevicular fluid and saliva of periodontitis patients. J Clin Periodontol. 1996;23:1127-32.
45. Seiki M. Membrane-type matrix metalloproteinases. APMIS. 1999;107:137-43.
46. Knauper V, Will H, Lopez-Otin C, Smith B, Atkinson SJ, Stanton H, et al. Cellular mechanisms for human procollagenase-3 (MMP-13) activation. Evidence that MT1-MMP (MMP-14) and gelatinase a (MMP-2) are able to generate active enzyme. J Biol Chem. 1996;271:17124-31.
47. Holopainen JM, Moilanen JA, Sorsa T, Kivela-Rajamaki M, Tervahartiala T, Vesaluoma MH, et al. Activation of matrix metalloproteinase-8 by membrane type 1-MMP and their expression in human tears after photorefractive keratectomy. Invest Ophthalmol Vis Sci. 2003;44:2550-6.
48. Sekine-Aizawa Y, Hama E, Watanabe K, Tsubuki S, Kanai-Azuma M, Kanai Y, et al. Matrix metalloproteinase (MMP) system in brain: identification and characterization of brain-specific MMP highly expressed in cerebellum. Eur J Neurosci. 2001;13:935-48.
49. Matsuda A, Itoh Y, Koshikawa N, Akizawa T, Yana I, Seiki M. Clusterin, an abundant serum factor, is a possible negative regulator of MT6-MMP/MMP-25 produced by neutrophils. J Biol Chem. 2003;278:36350-7.
50. Drew AF, Blick TJ, Lafleur MA, Tim EL, Robbie MJ, Rice GE, et al. Correlation of tumor- and stromal-derived MT1-MMP expression with progression of human ovarian tumors in SCID mice. Gynecol Oncol. 2004;95:437-48.
51. Toft-Hansen H, Nuttall RK, Edwards DR, Owens T. Key metalloproteinases are expressed by specific cell types in experimental autoimmune encephalomyelitis. J Immunol. 2004;173:5209-18.
52. Nie J, Pei D. Rapid inactivation of alpha-1-proteinase inhibitor by neutrophil specific leukolysin/membrane-type matrix metalloproteinase 6. Exp Cell Res. 2004;296:145-50.
53. Nie J, Pei D. Direct activation of pro-matrix metalloproteinase-2 by leukolysin/membrane-type 6 matrix metalloproteinase/matrix metalloproteinase 25 at the asn(109)-Tyr bond. Cancer Res. 2003;63:6758-62.
54. Emingil G, Kuula H, Sorsa T, Atilla G. Gingival crevicular fluid matrix metalloproteinase-25 and -26 levels in periodontal disease. J Periodontol. 2006;77:664-71.
55. Kazes I, Delarue F, Hagege J, Bouzhir-Sima L, Rondeau E, Sraer JD, et al. Soluble latent membrane-type 1 matrix metalloprotease secreted by human mesangial cells is activated by urokinase. Kidney Int. 1998;54:1976-84.
56. Li H, Bauzon DE, Xu X, Tschesche H, Cao J, Sang QA. Immunological characterization of cell-surface and soluble forms of membrane type 1 matrix metalloproteinase in human breast cancer cells and in fibroblasts. Mol Carcinog. 1998;22:84-94.
57. Cox SW, Eley BM, Kiili M, Asikainen A, Tervahartiala T, Sorsa T. Collagen degradation by interleukin-1β-stimulated gingival fibroblasts is accompanied by release and activation of multiple matrix metalloproteinases and cysteine proteinases. Oral Dis. 2006;12:34-40.
58. Maisi P, Prikk K, Sepper R, Pirilä E, Salo T, Hietanen J, et al. Soluble membrane-type 1 matrix metalloproteinase (MT1-MMP) and gelatinase A (MMP-2) in induced sputum and bronchoalveolar lavage fluid of human bronchial asthma and bronchiectasis. APMIS. 2002;110:771-82.
59. Folgueras AR, Pendas AM, Sanchez LM, Lopez-Otin C. Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int J Dev Biol. 2004;48:411-24.
60. Baker AH, Zaltsman AB, George SJ, Newby AC. Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis. J Clin Invest. 1998;101:1478-87.
61. Woessner JF Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 1991;5:2145-54.
62. Shibutani T, Yamashita K, Aoki T, Iwayama Y, Nishikawa T, Hayakawa T. Tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) stimulate osteoclastic bone resorption. J Bone Miner Metab. 1999;17:245-51.
63. Sobue T, Hakeda Y, Kobayashi Y, Hayakawa H, Yamashita K, Aoki T, et al. Tissue inhibitor of metalloproteinases 1 and 2 directly stimulate the bone-resorbing activity of isolated mature osteoclasts. J Bone Miner Res. 2001;16:2205-14.
64. Uitto VJ, Overall CM, McCulloch C. Proteolytic host cell enzymes in gingival crevice fluid. Periodontol 2000. 2003;31:77-104.
65. Birkedal-Hansen H. Role of matrix metalloproteinases in human periodontal diseases. J Periodontol. 1993;64:474-84.
66. Julovi SM, Yasuda T, Shimizu M, Hiramitsu T, Nakamura T. Inhibition of interleukin-1 beta-stimulated production of matrix metalloproteinases by hyaluronan via CD44 in human articular cartilage. Arthritis Rheum. 2004;50:516-25.
67. Liacini A, Sylvester J, Li WQ, Huang W, Dehnade F, Ahmad M, et al. Induction of matrix metalloproteinase-13 gene expression by TNF-alpha is mediated by MAP kinases, AP-1, and NF-kappaB transcription factors in articular chondrocytes. Exp Cell Res. 2003;288:208-17.
68. Damiens C, Fortun Y, Charrier C, Heymann D, Padrines M. Modulation by soluble factors of gelatinase activities released by osteoblastic cells. Cytokine. 2000;12:1727-31.
69. Johnson LL, Dyer R, Hupe DJ. Matrix metalloproteinases. Curr Opin Chem Biol. 1998;2:466-71.
70. Sorsa T, Salo T, Koivunen E, Tyynela J, Konttinen YT, Bergmann U, et al. Activation of type IV procollagenases by human tumor-associated trypsin-2. J Biol Chem. 1997;272:21067-74.
71. Moilanen M, Sorsa T, Stenman M, Nyberg P, Lindy O, Vesterinen J, et al. Tumor-associated trypsinogen-2 (trypsinogen-2) activates procollagenases (MMP-1, -8, -13) and stromelysin-1 (MMP-3) and degrades type I collagen. Biochemistry. 2003;42:5414-20.
72. Stenman M, Ainola M, Valmu L, Bjartell A, Ma G, Stenman UH, et al. Trypsin-2 degrades human type II collagen and is expressed and activated in mesenchymally transformed rheumatoid arthritis synovitis tissue. Am J Pathol. 2005;167:1119-24.
73. Sorsa T, Ingman T, Suomalainen K, Haapasalo M, Konttinen YT, Lindy O, et al. Identification of proteases from periodontopathogenic bacteria as activators of latent human neutrophil and fibroblast-type interstitial collagenases. Infect Immun. 1992;60:4491-5.
74. Okamoto T, Akuta T, Tamura F, van Der Vliet A, Akaike T. Molecular mechanism for activation and regulation of matrix metalloproteinases during bacterial infections and respiratory inflammation. Biol Chem. 2004;385:997-1006.
75. Potempa J, Banbula A, Travis J. Role of bacterial proteinases in matrix destruction and modulation of host responses. Periodontol 2000. 2000;24:153-92.
76. Bannikov GA, Karelina TV, Collier IE, Marmer BL, Goldberg GI. Substrate binding of gelatinase B induces its enzymatic activity in the presence of intact propeptide. J Biol Chem. 2002;277:16022-7.
77. Fedarko NS, Jain A, Karadag A, Fisher LW. Three small integrin binding ligand N-linked glycoproteins (SIBLINGs) bind and activate specific matrix metalloproteinases. FASEB J. 2004;18:734-6.
78. Sorsa T, Ding YL, Ingman T, Salo T, Westerlund U, Haapasalo M, et al. Cellular source, activation and inhibition of dental plaque collagenase. J Clin Periodontol. 1995;22:709-17.
79. McMillan SJ, Kearley J, Campbell JD, Zhu XW, Larbi KY, Shipley JM, et al. Matrix metalloproteinase-9 deficiency results in enhanced allergen-induced airway inflammation. J Immunol. 2004;172:2586-94.
80. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol. 2001;17:463-516.
81. Fini ME, Cook JR, Mohan R, Brinckerhoff CE. Regulation of matrix metalloproteinase gene expression. In: Parks WC, Mecham RP, editors. Matrix metalloproteinases. California: Academic Press; 1998. p. 299-356.
82. Shrivastava A, Radziejewski C, Campbell E, Zhu XW, Larbi KY, Shipley JM, et al. An orphan receptor tyrosine kinase family whose members serve as nonintegrin collagen receptors. Mol Cell. 1997;1:25-34.
83. Vogel W, Gish GD, Alves F, Pawson T. The discoidin domain receptor tyrosine kinases are activated by collagen. Mol Cell. 1997;1:13-23.
84. Uria JA, Jimenez MG, Balbin M, Freije JM, Lopez-Otin C. Differential effects of transforming growth factor-beta on the expression of collagenase-1 and collagenase-3 in human fibroblasts. J Biol Chem. 1998;273:9769-77.
85. Opdenakker G, Van den Steen PE, Dubois B, Nelissen I, Van Coillie E, Masure S, et al. Gelatinase B functions as regulator and effector in leukocyte biology. J Leukoc Biol. 2001;69:851-9.
86. Peppin GJ, Weiss SJ. Activation of the endogenous metalloproteinase, gelatinase, by triggered human neutrophils. Proc Natl Acad Sci U S A. 1986;83:4322-6.
87. Rutter JL, Mitchell TI, Buttice G, Meyers J, Gusella JF, Ozelius LJ, et al. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription.Cancer Res. 1998;58:5321-5.
88. Noll WW, Belloni DR, Rutter JL, Storm CA, Schned AR, Titus-Ernstoff L, et al. Loss of heterozygosity on chromosome 11q22-23 in melanoma is associated with retention of the insertion polymorphism in the matrix metalloproteinase-1 promoter. Am J Pathol. 2001;158:691-7.
89. Shimajiri S, Arima N, Tanimoto A, Murata Y, Hamada T, Wang KY, et al. Shortened microsatellite d(CA)21 sequence down-regulates promoter activity of matrix metalloproteinase 9 gene. FEBS Lett. 1999;455:70-4.
90. Przybylowska K, Zielinska J, Zadrozny M, Krawczyk T, Kulig A, Wozniak P, et al. An association between the matrix metalloproteinase 1 promoter gene polymorphism and lymph node metastasis in breast cancer. J Exp Clin Cancer Res. 2004;23:121-5.
91. Kanamori Y, Matsushima M, Minaguchi T, Kobayashi K, Sagae S, Kudo R, et al. Correlation between expression of the matrix metalloproteinase-1 gene in ovarian cancers and an insertion/deletion polymorphism in its promoter region. Cancer Res. 1999;59:4225-7.
92. Thiry-Blaise LM, Taquet AN, Reginster JY, Nusgens B, Franchimont P, Lapiere CM. Investigation of the relationship between osteoporosis and the collagenase gene by means of polymorphism of the 5′upstream region of this gene. Calcif Tissue Int. 1995;56:88-91.
93. de Souza AP, Trevilatto PC, Scarel-Caminaga RM, Brito RB, Line SR. MMP-1 promoter polymorphism: association with chronic periodontitis severity in a Brazilian population. J Clin Periodontol. 2003;30:154-8.
94. Santos MCL, Campos MIG, de Souza AP, Trevilatto PC, Line SR. Analysis of MMP-1 and MMP-9 promoter polymorphism in early osseointegrated implant failure. Int J Maxillofac Implants. 2004;19:38-43.
95. Cao Z, Li C, Jin L, Corbet EF. Association of matrix metalloproteinase-1 promoter polymorphism with generalized aggressive periodontitis in a Chinese population. J Periodontal Res. 2005;40:427-31.
96. Itagaki M, Kubota T, Tai H, Shimada Y, Morozumi T, Yamazaki K. Matrix metalloproteinase-1 and -3 gene promoter polymorphisms in Japanese patients with periodontitis. J Clin Periodontol. 2004;31:764-9.
97. Holla LI, Jurajda M, Fassmann A, Dvorakova N, Znojil V, Vacha J. Genetic variations in the matrix metalloproteinase-1 promoter and risk of susceptibility and/or severity of chronic periodontitis in the Czech population. J Clin Periodontol. 2004;31:685-90.
98. Zhang B, Ye S, Herrmann SM, Eriksson P, de Maat M, Evans A, et al. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation. 1999;99:1788-94.
99. Wang J, Warzecha D, Wilcken D, Wang XL. Polymorphism in the gelatinase B gene and the severity of coronary arterial stenosis. Clin Sci (Lond). 2001;101:87-92.
100. Fiotti N, Zivadinov R, Altamura N, Nasuelli D, Bratina A, Tommasi MA, et al. MMP-9 microsatellite polymorphism and multiple sclerosis. J Neuroimmunol. 2004;152:147-53.
101. Wagner S, Kluge B, Koziol JA, Grau AJ, Grond-Ginsbach C. MMP-9 polymorphisms are not associated with spontaneous cervical artery dissection. Stroke. 2004;35:e62-4.
102. Nelissen I, Vandenbroeck K, Fiten P, Hillert J, Olsson T, Marrosu MG, et al. Polymorphism analysis suggests that the gelatinase B gene is not a susceptibility factor for multiple sclerosis. J Neuroimmunol. 2000;105:58-63.
103. Peters DG, Kassam A, St Jean PL, Yonas H, Ferrell RE. Functional polymorphism in the matrix metalloproteinase-9 promoter as a potential risk factor for intracranial aneurysm. Stroke. 1999;30:2612-6.
104. de Souza AP, Trevilatto PC, Scarel-Caminaga RM, de Brito RB Jr, Barros SP, Line SR. Analysis of the MMP-9 (C-1562 T) and TIMP-2 (G-418C) gene promoter polymorphisms in patients with chronic periodontitis. J Clin Periodontol. 2005;32:207-11.
105. Ye S, Watts GF, Mandalia S, Humphries SE, Henney AM. Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis. Br Heart J. 1995;73:209-15.
106. de Maat MP, Jukema JW, Ye S, Zwinderman AH, Moghaddam PH, Beekman M, et al. Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis. Am J Cardiol. 1999;83:852-6.
107. Terashima M, Akita H, Kanazawa K, Inoue N, Yamada S, Ito K, et al. Stromelysin promoter 5A/6A polymorphism is associated with acute myocardial infarction. Circulation. 1999;99:2717-9.
108. Ye S. Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases. Matrix Biol. 2000;19:623-9.
109. Holla LI, Fassmann A, Vasku A, Goldbergova M, Beranek M, Znojil V, et al. Genetic variations in the human gelatinase A (matrix metalloproteinase-2) promoter are not associated with susceptibility to, and severity of, chronic periodontitis. J Periodontol. 2005;76:1056-60.
110. Kinane DF, Shiba H, Hart TC. The genetic basis of periodontitis. Periodontol 2000. 2005;39:91-117.
111. Loos BG, John RP, Laine ML. Identification of genetic risk factors for periodontitis and possible mechanisms of action. J Clin Periodontol. 2005;32:159-79.
112. Ryan ME, Carnu O, Kamer A. The influence of diabetes on periodontal tissues. J Amer Dent Assoc. 2003;134:395-405.
113. Meurman JH, Janket SJ, Qvarnstrom M, Nuutinen P. Dental infections and serum inflammatory markers in patients with and without severe heart disease. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003;96:695-700.
114. Zhou Z, Apte SS, Soininen R, Cao R, Baaklini GY, Rauser RW, et al. Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc Natl Acad Sci U S A. 2000;97:4052-7.
115. Milner JM, Cawston TE. Matrix metalloproteinase knock-out studies and the potential use of matrix metalloproteinase inhibitors in the rheumatic diseases. Curr Drug Targets Inflamm Allergy. 2005;4:363-75.
116. Sorsa T, Tervahartiala T, Stenman M, Suomalainen K, Mäntylä P. Chair-side diagnostic point-of-care MMP tools in periodontitis and peri-implantitis. Nordic Dentistry. Copenhagen: Quintessence Int, Schou L; 2004. p. 79-95.
117. Sorsa T, Mantyla P, Ronka H, Kallio P, Kallis GB, Lundqvist C, et al. Scientific basis of a matrix metalloproteinase-8 specific chair-side test for monitoring periodontal and peri-implant health and disease. Ann N Y Acad Sci. 1999;878:130-40.
118. Sorsa T, Uitto VJ, Suomalainen K, Vauhkonen M, Lindy S. Comparison of interstitial collagenases from human gingiva, sulcular fluid and polymorphonuclear leukocytes. J Periodontal Res. 1988;23:386-93.
119. Sorsa T, Suomalainen K, Uitto VJ. The role of gingival crevicular fluid and salivary interstitial collagenases in human periodontal diseases. Arch Oral Biol. 1990;35:193S-196S.
120. Sorsa T, Ding Y, Salo T, Lauhio A, Teronen O, Ingman T, et al. Effects of tetracyclines on neutrophil, gingival, and salivary collagenases. A functional and western-blot assessment with special reference to their cellular sources in periodontal diseases. Ann N Y Acad Sci. 1994;732:112-31.
121. Kivelä-Rajamäki MJ, Teronen OP, Maisi P, Husa V, Tervahartiala TI, Pirila EM, et al. Laminin-5 gamma2-chain and collagenase-2 (MMP-8) in human peri-implant sulcular fluid. Clin Oral Implants Res. 2003;14:158-65.
122. Kivelä-Rajamäki M, Maisi P, Srinivas R, Tervahartiala T, Teronen O, Husa V, et al. Levels and molecular forms of MMP-7 (matrilysin-1) and MMP-8 (collagenase-2) in diseased human peri-implant sulcular fluid. J Periodontal Res. 2003;38:583-90.
123. Golub LM, Lee HM, Ryan ME, Giannobile WV, Payne J, Sorsa T. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res. 1998;12:12-26.
124. Preshaw PM, Hefti AF, Jepsen S, Etienne D, Walker C, Bradshaw MH. Subantimicrobial dose doxycycline as adjunctive treatment for periodontitis. A review. J Clin Periodontol. 2004;31:697-707.
125. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science. 2002;295:2387-92.
126. Koivunen E, Arap W, Valtanen H, Rainisalo A, Medina OP, Heikkila P, et al. Tumor targeting with a selective gelatinase inhibitor. Nat Biotechnol. 1999;17:768-74.
127. Bjornsson MJ, Havemose-Poulsen A, Stoltze K, Holmstrup P. Influence of the matrix metalloproteinase inhibitor batimastat (BB-94) on periodontal bone destruction in Sprague-Dawley rats. J Periodontal Res. 2004;39:269-74.
128. Sorsa T, Golub LM. Is the excessive inhibition of matrix metalloproteinases (MMPs) by potent synthetic MMP inhibitors (MMPIs) desirable in periodontitis and other inflammatory diseases? That is: 'Leaky' MMPIs vs excessively efficient drugs. Oral Dis. 2005;11:408-9.
129. Ashley RA. Clinical trials of a matrix metalloproteinase inhibitor in human periodontal disease. SDD Clinical Research Team. Ann N Y Acad Sci. 1999;878:335-46.
130. Craig RG, Yip JK, So MK, Boylan RJ, Socransky SS, Haffajee AD. Relationship of destructive periodontal disease to the acute-phase response. J Periodontol. 2003;74:1007-16.
131. D'Aiuto F, Parkar M, Andreou G, Suvan J, Brett PM, Ready D, et al. Periodontitis and systemic inflammation: control of the local infection is associated with a reduction in serum inflammatory markers. J Dent Res. 2004;83:156-60.
132. Golub LM, Payne JB, Reinhardt RA, Nieman G. Can systemic diseases co-induce (not just exacerbate) periodontitis. A hypothetical 'two-hit' model. J Dent Res. 2006;85:102-05.
133. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557-65.
134. Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G, et al. AtheroGene Investigators. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation. 2003;107:1579-85.
135. Brown DL, Desai KK, Vakili BA, Nouneh C, Lee HM, Golub LM. Clinical and biochemical results of the metalloproteinase inhibition with subantimicrobial doses of doxycycline to prevent acute coronary syndromes (MIDAS) pilot trial. Arterioscler Thromb Vasc Biol. 2004;24:733-8.
136. Brown DL, Golub LM, Lee HM, Desai K, Sorsa T, Greenwald R. Effect of sub-antimicrobial doxycycline on biomarkers in patients with acute coronary syndromes. J Dent Res. 2003;82:abstract 1443.
137. Eley BM, Cox SW. Advances in periodontal diagnosis. 8. Commercial diagnostic kits based on GCF proteolytic and hydrolytic enzyme levels. Br Dent J. 1998;184b:373-6.
138. Mantyla P, Stenman M, Kinane DF, Tikanoja S, Luoto H, Salo T, et al. Gingival crevicular fluid collagenase-2 (MMP-8) test stick for chair-side monitoring of periodontitis. J Periodontal Res. 2003;38:436-9.
139. Golub LM, Lee HM, Greenwald RA, Ryan ME, Sorsa T, Salo T, et al. A matrix metalloproteinase inhibitor reduces bone-type collagen degradation fragments and specific collagenases in gingival crevicular fluid during adult periodontitis. Inflamm Res. 1997;46:310-9.
140. Emingil G, Atilla G, Sorsa T, Luoto H, Kirilmaz L, Baylas H. The effect of adjunctive low-dose doxycycline therapy on clinical parameters and gingival crevicular fluid matrix metalloproteinase-8 levels in chronic periodontitis. J Periodontol. 2004;75:106-15.
141. Ryan ME, Ramamurthy S, Golub LM. Matrix metalloproteinases and their inhibition in periodontal treatment. Curr Opin Periodontol. 1996;3:85-96.
142. Apajalahti S, Sorsa T, Railavo S, Ingman T. The in vivo levels of matrix metalloproteinase-1 and -8 in gingival crevicular fluid during initial orthodontic tooth movement. J Dent Res. 2003;82:1018-22.
143. Ingman T, Apajalahti S, Mantyla P, Savolainen P, Sorsa T. Matrix metalloproteinase-1 and -8 in gingival crevicular fluid during orthodontic tooth movement: a pilot study during 1 month of follow-up after fixed appliance activation. Eur J Orthod. 2005;27b:202-7.
144. Lauhio A, Salo T, Ding Y, Konttinen YT, Nordstrom D, Tschesche H, et al. In vivo inhibition of human neutrophil collagenase (MMP-8) activity during long-term combination therapy of doxycycline and non-steroidal anti-inflammatory drugs (NSAID) in acute reactive arthritis. Clin Exp Immunol. 1994;98:21-8.
145. Lauhio A, Salo T, Tjaderhane L, Lahdevirta J, Golub LM, Sorsa T. Tetracyclines in treatment of rheumatoid arthritis. Lancet. 1995;346:645-6.
146. Fingleton B, Menon R, Carter KJ, Overstreet PD, Hachey DL, Matrisian LM, et al. Proteinase activity in human and murine saliva as a biomarker for proteinase inhibitor efficacy. Clin Cancer Res. 2004;10:7865-74.
147. Nordstrom D, Lindy O, Lauhio A, Sorsa T, Santavirta S, Konttinen YT. Anti-collagenolytic mechanism of action of doxycycline treatment in rheumatoid arthritis. Rheumatol Int. 1998;17:175-80.
148. Valleala H, Teronen O, Friman C, Sorsa T, Solovieva S, Konttinen YT. Inhibition of collagenase by a bisphosphonate-group drug in patients with rheumatoid arthritis. J Rheumatol. 2000;27:1570-2.
149. Määttä M, Kari O, Tervahartiala T, Peltonen S, Kari M, Saari M, et al. Tear fluid levels of MMP-8 are elevated in ocular rosacea-modulation by oral doxycycline. Graefes Arch Clin Exp Ophtalmol. 2006;13:1-6.
150. Agarwal D, Goodison S, Nicholson B, Tarin D, Urquidi V. Expression of matrix metalloproteinase 8 (MMP-8) and tyrosinase-related protein-1 (TYRP-1) correlates with the absence of metastasis in an isogenic human breast cancer model. Differentiation. 2003;71:114-25.
151. Elkington PT, O'Kane CM, Friedland JS. The paradox of matrix metalloproteinases in infectious disease. Clin Exp Immunol. 2005;142:12-20.